Semaphorin 4D产品信息
英文名称：Semaphorin 4D
中文名称：脑信号蛋白4D
靶点别称：SEMA4D,CD100
物种：Human
属性：Protein
标记：Unconjugated
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>95% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Semaphorin 4D分子背景
Cluster of Differentiation 100 (CD100) is also known as Semaphorin-4D (SEMA4D), is a single-pass type I membrane protein which belongs to the semaphorin family, and is a human 150-kDa homodimer expressed at the surface of most hemopoietic cells. Semaphorin genes encode soluble and membrane-bound proteins, most of which have been shown to act as chemorepellents on growth cone guidance. CD100 is discrete, as it is a transmembrane leukocyte surface molecule that can also exist in a soluble form. Semaphorin 4D (Sema 4D) is an axon guidance molecule which is secreted by oligodendrocytes and induces growth cone collapse in the central nervous system. By binding plexin B1 receptor it functions as an R-Ras GTPase-activating protein (GAP) and repels axon growth cones in both the mature central nervous system. In the immune system, CD100 binds CD72 to activate B cells and dendritic cells, though much about this interaction is still under investigation. It is involved in oligodendrogenesis during development and during recovery from ischemic injury.
关键字： Semaphorin 4D;Semaphorin 4D蛋白;SEMA4D蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。